Zoetis: Focusing On The High Margin Segments
Zoetis divests its MFA segment to boost margins while focusing on profitable areas like genetics. Click here to find out why ...
Pet drug maker adding death, seizures to warning label on popular medication
A pet drug maker is making a big change on their labels for their new arthritis shot after Action 9 found pets getting really ...
John O'Groat Journal10d
Owner claims her dog became zombie-like, vomits frequently and walks like a crab after taking controversial arthritis drug
A Caithness woman claims that a drug given to alleviate her dog’s arthritis has caused serious adverse effects and has ...
Yahoo Finance19d
Zoetis (ZTS) Declined in Q4 Despite Posting Excellent Results
Zoetis Inc. (NYSE: ZTS ... the stock has come under pressure due to concerns about the growth prospects of Librela, its biologic drug for pain in dogs (as well as Solensia, the sister drug ...
Insider Monkey24d
10 Best Weight Loss Drug Stocks to Buy According to Analysts
Zoetis Inc. (NYSE:ZTS ... especially with products like Simparica and Librela. Revenue from livestock also increased, which was driven by innovative vaccines and solutions. The company’s ...
The Motley Fool1mon
A Once-in-a-Decade Opportunity: 1 Magnificent S&P 500 Dividend Stock Down 36% to Double Up on Right Now
Zoetis' newest blockbusters are its osteoarthritis (OA) pain treatments for dogs and cats: Librela and Solensia. These monoclonal antibodies offer improved efficacy compared to traditional non ...
The Weekly Times26d
US authorities list “death” as an adverse side effect of dog drug
Canine osteoarthritis drug Beransa information on manufacturer Zoetis website. The FDA advised vets that if a dog under their care experiences an adverse event while receiving Librela ...